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ABSTRACT
Objectives To date the reported outcomes of surgical 
aortic valve replacement (SAVR) are mainly in the 
settings of trials comparing it with evolving transcatheter 
aortic valve implantation. We set out to examine 
characteristics and outcomes in people who underwent 
SAVR reflecting a national cohort and therefore ‘real- 
world’ practice.
Design Retrospective analysis of prospectively collected 
data of consecutive people who underwent SAVR with 
or without coronary artery bypass graft (CABG) surgery 
between April 2013 and March 2018 in the UK. This 
included elective, urgent and emergency operations. 
Participants’ demographics, preoperative risk factors, 
operative data, in- hospital mortality, postoperative 
complications and effect of the addition of CABG to SAVR 
were analysed.
Setting 27 (90%) tertiary cardiac surgical centres in the 
UK submitted their data for analysis.
Participants 31 277 people with AVR were identified. 
19 670 (62.9%) had only SAVR and 11 607 (37.1%) had 
AVR +CABG.
Results In- hospital mortality for isolated SAVR was 1.9% 
(95% CI 1.6% to 2.1%) and was 2.4% for AVR+CABG. 
Mortality by age category for SAVR only were: <60 
years=2.0%, 60–75 years=1.5%, >75 years=2.2%. For 
SAVR+CABG these were; 2.2%, 1.8% and 3.1%. For 
different categories of EuroSCORE, mortality for SAVR in 
low risk people was 1.3%, in intermediate risk 1% and 
for high risk 3.9%. 74.3% of the operations were elective, 
24% urgent and 1.7% emergency/salvage. The incidences 
of resternotomy for bleeding and stroke were 3.9% and 
1.1%, respectively. Multivariable analyses provided no 
evidence that concomitant CABG influenced outcome. 
However, urgency of the operation, poor ventricular 
function, higher EuroSCORE and longer cross clamp 
and cardiopulmonary bypass times adversely affected 
outcomes.
Conclusions Surgical SAVR±CABG has low mortality 
risk and a low level of complications in the UK in people 
of all ages and risk factors. These results should inform 
consideration of treatment options in people with aortic 
valve disease.
BACKGROUND
Aortic valve disease, especially aortic stenosis 
affects 5% of the population and 3.9% of 
those between the ages of 70 and 79 and 
nearly 10% of those above the age of 80.1 
Severe aortic stenosis when untreated has 
a risk of death of 50% at 2 years.2 Conven-
tionally the gold standard of treatment 
has been surgical aortic valve replacement 
(SAVR). However, the role of transcatheter 
aortic valve implantation (TAVI) has evolved 
in recent years. TAVI was first introduced in 
2002, initially being performed in high risk 
inoperable patients.3 The original Placement 
of Aortic Transcatheter Valves (PARTNER) 
Strengths and limitations of this study
 ► This is a large study of consecutive participants 
who have undergone surgical aortic valve replace-
ment ±coronary artery bypass graft surgery in the 
UK, reporting contemporary outcomes.
 ► This study includes people of all age groups and 
risks factors, and elective as well as urgent and 
emergency operations.
 ► The results are of in- hospital mortality and com-
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trial demonstrated a significant reduction in mortality, 
repeat hospitalisation and cardiac symptoms compared 
with inoperable patients who had only medical therapy.4 
The original PIVOTAL study also demonstrated signifi-
cantly higher survival at 1 year in high- risk patients who 
underwent SAVR.5
The role of TAVI is being extended to lower risk and 
younger patients based on recent trials comparing SAVR 
with TAVI.6 7 Several studies suggest there has been a 
change in demographics and types of surgical valves used 
since the advent of TAVI.8–10 There has been a trend of 
increased use of tissue valves and a decrease in the use of 
mechanical valves in recent years.11 This may be due to 
the evolution of TAVI practice whereby younger patients 
can have a tissue valve with the view that they have a TAVI 
valve in the future when the tissue valve has deteriorated, 
so called valve- in- valve.12 13
The series in the literature reporting outcomes of SAVR 
are generally unit based.9 14 Also, people with aortic valve 
disease are given information about the outcomes of 
SAVR which may be out of date and incorrectly extrap-
olated from smaller studies. There is a lack of contem-
porary national data to assess the outcomes of SAVR 
(mortality and complications), and to demonstrate the 
trend in use of prosthetic valves which would inform 
people with aortic valve disease better. There are some 
perceived complications of surgery that may be under-
stood by referring general practitioners and cardiologists 
to be prohibitive risks for surgery.
In order to inform practitioners, people with aortic 
valve disease and the cardiac surgical community, we set 
out to examine the results of contemporaneous SAVR in a 
multicentre study of UK cardiac surgical units, in the era 
of TAVI. In addition, we summarise and interpret some of 




This is an analysis of prospectively collected data of people 
who underwent SAVR±coronary artery bypass graft 
(CABG) surgery between April 2013 and March 2018 in 
the UK and Republic of Ireland. Anonymised data were 
submitted to the Society for Cardiothoracic Surgery of 
Great Britain & Ireland for 27 of the 30 units and then 
stored in a secure database. This period was chosen to 
reflect fairly contemporary practice and also the data is 
submitted in March every year. The data are collected by 
each unit, validated and then submitted to the National 
Institute of Cardiovascular Outcome Research (NICOR). 
It took approximately 9 months to collect, validate and 
clean all the data. The outcome measures recorded are 
based on strict definitions provided by NICOR to provide 
uniformity.
Only participants who had had first time surgery, 
SAVR±CABG were included. All participants immaterial 
of their risk for surgery, people of all age groups and 
risk factors were included. Those who required other 
concomitant procedures like replacement of parts of the 
aorta, aortic root enlargement, other valve procedures 
and redo surgery were excluded.
Pre-operative risk factors and operative features
Baseline demographic data; significant medical history 
such as diabetes, renal dysfunction, hypertension or 
stroke; predominant aortic valve pathology (stenosis or 
regurgitation or mixed valve disease) and preoperative 
left ventricular ejection fraction (LVEF) were collected. 
EuroSCORE is the risk stratification model used in the 
UK. Logistic EuroSCORE was collected as well as Euro-
SCORE II where available. The latter was only used since 
2017 and therefore not available for all participants. 
Logistic EuroSCORE was divided into three categories: 
<3%, 3%–6%, >6%.
LVEF was divided into three categories: good (EF >50%), 
moderate (EF 30%–50%) and poor (EF <30%). Tran-
sient ischaemic attack was defined as any neurological 
symptoms lasting <24 hours. Stroke was defined as new 
neurological dysfunction persisting >24 hours. Operative 
data including operative urgency: elective, urgent and 
emergency/salvage were recorded. Elective was defined 
as when the person was admitted from home, urgent 
meaning that the person was admitted with an urgent 
condition and required surgery during the same hospital 
admission, emergency and salvage meaning that surgery 
was required within 24 hours of admission and/or the 
person was in extremis. Other parameters including 
cardiopulmonary bypass (CPB) time, cross clamp time 
(CCT), type of valve implanted as well as concomitant 
CABG surgery performed were also collected.
Postoperative outcomes
Postoperative complication data were collected with the 
main focus being in- hospital mortality, new stroke, return 
to theatre for bleeding, deep sternal wound infection and 
duration of postoperative hospital stay.
Statistical analysis
Once the records for all participants were collated and the 
data cleaned, each factor was summarised using descrip-
tive methods. Categorical variables are presented as N 
(%) and continuous variables are presented as median 
(IQR). New strokes were recoded to be either no stroke 
or any cerebrovascular accident (transient or perma-
nent). The natural log of postoperative length of stay 
(days) was used due to positive skewed distribution of this 
variable. Univariate models were used, logistic regression 
for binary outcomes and linear regression for continuous 
outcomes, to assess the impact of the key explanatory vari-
ables. In these models, a two- tailed p <0.05 was consid-
ered significant. The population analysed included all the 
participants with data collected, with results checked in 
the subset who had SAVR only (without CABG). Building 
on this, a multivariable model with all key variables in the 
model to assess which had the most impact on each of 
 on N
ovem









pen: first published as 10.1136/bm













































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm





4 Jahangiri M, et al. BMJ Open 2021;11:e046491. doi:10.1136/bmjopen-2020-046491
Open access 
the outcomes was created. Stata/MP V.15.1 (StataCorp) 
was used for all analyses. Multiple imputation of missing 
data was not performed. The missingness was mostly 
negligible. There was no missing mortality and the data 
is shown in table 1.
Patient and public involvement




In total 31 277 patients were included. Of these, 19 670 
(62.9%) had only SAVR and 11 607 (37.1%) had 
SAVR +CABG. There were 14.4% below the age of 60, 
46.9% between 60 to 75% and 36.7% older than 75 years 
with 7.9% missing age data. There were 1.9 times more 
males than females (10.3% missing).
Regarding preoperative risk factors, 75.2% had good 
LVEF, 17.3% had moderate and 4.3% had poor LVEF. 
74.3% of the operations were elective, 24% were urgent 
and 1.7% were emergency or salvage operations.
Logistic EuroSCORE had a median of 1.83 with an IQR 
of 0.06–6.0. In total, 50% of patients were classified as low 
risk (<3%), 16% as medium risk (3—6%) and 22% high 
risk (>6%). 3792 patients (12.1%) were missing data. The 
median EuroSCORE II was 1.95 (IQR 0.67–4.8) although 
with 56.5% with missing data, as this was introduced into 
the database in 2017. The median CPB time was 104 min 
(IQR 82–135) and CCT was 79 min (IQR 61–101).
For valve implant replacement type, 70% had a tissue 
valve, 12.2% a mechanical valve and 0.2% had homograft 
or autograft valves. For 17.3% the entry for valve type was 
unclear. The ratio of mechanical implant to bioprosthetic 
implant use has remained stable over time.
Overall mortality was 2.4% (95% CI 2.2% to 2.6%) and 
mortality for isolated SAVR for all participants was 1.9% 
(95% CI 1.6% to 2.1%). The mortality figures analysed 
for different age ranges and for categories of EuroSCORE 
are shown in table 2.
Overall, 3.9% (3.6% in SAVR only) of participants had 
resternotomy for postoperative bleeding or tamponade, 
0.04% (0.06% in SAVR only) had reoperation for valvular 
problems (significant paravalvular leak and early endo-
carditis), 0.7% (0.6% SAVR only) had reoperation for 
other cardiac problems, 0.2% (0.15% for SAVR only) had 
rewiring of sternum for sterile wounds and 0.14% (0.06% 
for SAVR only) had rewiring of sternum for infection. 
Transient ischaemic attack occurred in only 0.6% and 
1.1% had a stroke (no missing data).
Median postoperative length of stay was 7 days (IQR: 
6–11) in those with SAVR only and 8 days (IQR: 6–12) in 
all patients.
The number of bypass grafts was not analysed due to 
concerns about inconsistent reporting of data describing 
the number of grafts.
When comparing the two subsets of patients, the char-
acteristics of those with SAVR alone were broadly similar 
to those with SAVR+CABG. In SAVR alone there were 
more people aged <60 years (19.3% vs 6.2%), but less 
people were older than 75 (30.1% vs 43%). A higher 
proportion of those with SAVR+CABG were male (68% vs 
54%). Bypass time was an average of 37 min shorter and 
CCT 27 min in the SAVR alone group. Among those with 




Taken in isolation, all preoperative risk factors were asso-
ciated with an increased odds of death, as was addition of 
CABG. The same pattern was observed when analysing 
the need for reoperation or surgery, with all explanatory 
variables indicative of a worse outcome without taking 
into account any others. For new stroke only age, Euro-
SCORE, operative urgency, EF and cumulative bypass and 
CCT affected a negative outcome (but not gender), as did 
CABG. All factors predicted a longer postoperative length 
of stay, including CABG.
As a sensitivity analysis, age categories were also 
assessed. When included as a continuous variable, age was 
significant both on its own and in all the multivariable 
models. All participants were categorised into <60, 60–75 
and >75 years of age. Those 60–75 were at a lower odds of 
death in comparison to those <60 (OR 0.71, 95% CI 0.53 
to 0.95, p=0.021) with no difference in those >75 (OR 
1.09, 95% CI 0.82 to 1.45) in the AVR alone group. These 
findings were different in the SAVR+CABG group, with 
no significant difference in those 60–75 (OR 0.81, 95% CI 
0.64 to 1.03) but an increased risk in those >75 (OR 1.09, 
95% CI 1.12 to 1.76, p=0.004).
Multivariable analyses
Analysis of postoperative outcomes using multivariable 
models including all preoperative and operative factors 
are shown in table 1. This demonstrated that age (OR 
1.03 (95% CI 1.02 to 1.04), p<0.001), moderate EF (OR 
1.48 (95% CI 1.18 to 1.85), p<0.001), poor EF (OR 1.90 







<3% 15 619 (50.0) 2.0 1.3
3%–6% 5020 (16.1) 0.9 1.0
>6% 6846 (21.9) 4.4 3.9
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(95% CI 1.36 to 2.69), p<0.001), logistic EuroSCORE 
(OR 1.02 (95% CI 1.02 to 1.03), p<0.001), urgent opera-
tion (OR 1.63 (95% CI 1.30 to 2.00, p<0.001), emergency 
surgery (OR 6.87 (95% CI 4.70 to 10.16), p<0.001) and 
longer CPB times affected mortality (OR 1.02 (95% CI 
1.01 to 1.02), p<0.001).
When all other variables were taken into account CABG 
was not significantly associated with an increase in the risk 
of death (OR 1.15 (95% CI 0.93 to 1.42), p=0.20).
Older age, (OR 1.01 (95% CI 1.00 to 1.01), p<0.006), 
longer CPB time (OR 1.00 (95% CI 1.00 to 1.01), 
p<0.001), urgent (OR 1.26 (95% CI 1.08 to 2.00), 
p<0.002) and emergency surgery (OR 2.22 (95% CI 1.51 
to 3.26), p<0.001) were significant factors in identifying 
people requiring return to theatre for bleeding. Again, 
CABG did not affect the odds of returning to theatre (OR 
1.07 (95% CI 0.93 to 1.24), p=0.33).
Factors affecting stroke were age, (OR 1.02 (95% CI 
1.01 to 1.03), p<0.001), emergency (OR 7.65 (95% CI 
5.00 to 11.70, p<0.001) or salvage surgery (OR 4.38 (95% 
CI 1.47 to 13.1) p=0.008) and CPB times (OR 1.00 (95% 
CI 1.00 to 1.01), p<0.001). As in the other outcomes, 
addition of CABG did not affect the outcome (OR 1.12 
(95% CI 0.88 to 1.42), p=0.37).
Age, male gender, moderate and poor EF, operative 
urgency, higher logistic EuroSCORE and cumulative 
bypass time significantly all affected postoperative length 
of stay.
DISCUSSION
This study reports contemporary results of SAVR and 
SAVR + CABG in the UK, reflecting real world practice, 
reporting an overall mortality of 1.9% and 2.4%, respec-
tively. We have shown a low mortality and complication 
rate for all comers following surgery in people requiring 
SAVR or SAVR + CABG. The complications were low with 
3.9% resternotomy for bleeding, 0.04% reoperation for 
valvular problems and 1.1% stroke. Surprisingly, having 
accounted for other risk factors, addition of CABG did 
not adversely affect the outcomes.
The strengths of the study include its large number 
of participants, no exclusion of urgent and emergency/
salvage cases, and inclusion of all risk participants. The 
limitations are that three centres were unable to take 
part, possible coding errors in using large databases, lack 
of detailed echocardiographic data on valve annular size 
and presence or absence of preoperative infective endo-
carditis which can adversely affect outcomes. In addition, 
the results are in- hospital mortality and complications 
and the database lacks longer follow- up information.
Data from the current study are consistent with other 
large international studies. Data from the US Society of 
Thoracic Surgeons (STS) database demonstrated in- hos-
pital mortality for isolated SAVR of 2.5% and incidence 
of stroke of 1.5%.15 A recent analysis of the Japanese 
Cardiovascular Surgery database which assessed the 
outcomes of patients undergoing SAVR over a 8- year 
period has demonstrated a similar in- hospital mortality 
of 2%.16 They also demonstrated a reduction in mortality 
over time, despite increasing surgical risk. The age of 
the patients in our study is lower than some of the trials 
of SAVR and TAVI. This is probably due to the selection 
criteria in these trials where older patients were selected.
We had set out to analyse the results of SAVR in the 
UK to inform practitioners treating people with aortic 
valve disease and inform people with this condition in 
an era where other therapies for management of aortic 
valve disease are evolving with expanding indications. 
Although the current study did not examine people 
who received TAVI, we discuss the various trials of SAVR 
and TAVI reported in the context of the literature and 
compare them with the results of the current study.
In tables 3–5, the demographics, procedural details 
and outcomes of the current study are compared with the 
respective sub- groups of the published trials. Table 5 shows 
low mortality and complication rate in the participants 
of this study following surgery in people who required 
SAVR or SAVR+ CABG. The trials comparing AVR and 
TAVI have enrolled and classified patients according to 
the risk of surgery, in particular the more recent trials.6 7 
The most commonly used surgical risk stratification score 
is the STS risk score, although this scoring system has 
been validated in the US population. We have used Euro-
SCORE and shown that mortality is low in all categories 
of risk.
There are several recent trials comparing SAVR with 
TAVI. A meta- analysis of six of these trials performed 
by Barili et al reported that mortality was affected by 
the treatment modality with a time- varying effect: TAVI 
was related to better survival in the first months after 
implantation whereas, after 40 months, it was a risk 
factor for all- cause mortality.17 The NOTION trial, 
which compared outcomes of patients estimated to 
have low surgical risk who underwent either TAVI or 
SAVR demonstrated similar early mortality results, with 
mortality of 2.1% in TAVI group vs 3.7% in the SAVR 
group, p=0.380.18 The PIVOTAL trial of low- risk patients 
also reported similar results between those who under-
went TAVI compared with SAVR, with early mortality of 
0.5% in TAVI group and 1.3% in SAVR.7 In addition, 
the 5- year results of the PARTNER 2 study, comparing 
TAVI versus SAVR in intermediate surgical risk demon-
strated no significant difference in the incidence of 
death or stroke at 5 years following SAVR or TAVI.19 The 
mortality in the intermediate EuroSCORE risk cate-
gory of the current study was 1.0% for SAVR only and 
0.9% for SAVR + CABG. PARTNER 3, however, demon-
strated significantly lower mortality in the TAVI group 
compared with SAVR (1% vs 2.5%, p=0.01) at 1 year.6 An 
observational study of 7618 patients comparing SAVR 
with TAVI at 5 years showed, however, that in a real- 
world population with low and intermediate risk, SAVR 
was associated with lower mortality and major adverse 
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Role of coexistent coronary artery disease and its 
management
Sixty per cent of patients with aortic valve disease under-
going SAVR and 65% of those undergoing TAVI have 
coexisting coronary artery disease.21 In our series, 37% 
had coexistent coronary artery disease and underwent 
concomitant CABG. The addition of CABG did not 
adversely affect outcomes. The USA15 and Japanese16 series 
did not look into concomitant CABG. The percentage 
of concomitant CABG in our series is higher than the 
trials of SAVR/TAVI. This probably reflects the selec-
tion criteria in the latter. In PARTNER 2, although both 
groups had a similar number with coexistent coronary 
artery disease, 14.5% of the SAVR group had concomitant 
CABG compared with 3.9% of the TAVI group who had 
percutaneous intervention (table 4).22 SAVR may, there-
fore, be the preferred treatment modality in those with 
aortic stenosis and multivessel coronary artery disease 
requiring revascularisation.
Treatment of coronary artery disease in TAVI patients 
may require more than one hospital admission and can 
often result in incomplete revascularisation and its conse-
quent increased morbidity and mortality. A meta- analysis 
by Sankaramangalam et al demonstrated that while there 
was no increase in mortality in patients with coronary 
artery disease who underwent TAVI at 30 days, there was 
a significant increase in mortality at 1 year following TAVI 
in these patients.23 The economic costs of readmission 
after TAVI have been demonstrated to be higher than in 
those who are readmitted after surgery and so untreated 
coronary disease which later requires readmission will 
have cost implications.24 25 Surgery has the advantage of 
addressing all the pathology with one operation.
Durability and choice of prosthetic valves
In choosing the technique of treatment for aortic valve 
disease, life expectancy of the person and durability of 
the valve need to be considered. Ideally, the prosthetic 
valve should be durable for the person’s lifetime. Both of 
these are related to person’s age. In the UK, a 50- year- old 
woman has a life expectancy of 34 years and a 70- year- old 
man a life expectancy of 14 years.26
The durability of bioprosthetic valves is well docu-
mented in the surgical literature and is inversely propor-
tional to person’s age. Structural valve deterioration has 
been demonstrated to increase exponentially beyond 
10 years following surgery.27 28 Considering the UK life 
expectancy,26 a 70- year- old man has a 5% risk of reop-
eration and a 50- year- old woman has a 30% chance of 
needing a second operation.
Surgery has the advantage of offering the patient 
a mechanical or a bioprosthetic valve. The option of a 
mechanical valve which is only available in surgical SAVR 
should not be overlooked especially in younger people. 
In the current study, we have shown a fairly consistent 
ratio of tissue to mechanical valve use. However, the 
reported literature shows that the number of mechan-
ical valve implantations has reduced in comparison to 
bioprosthetic valves.10 Mechanical valves are durable, with 
one group reporting 6.9% reintervention rate at 15 years 
vs 12.1% in those who underwent surgery with a biopros-
thesis.29 For this reason, it has been the most commonly 
considered prosthesis in those under the age of 60, as 
in our study where 60.2% of participants <60 years had 
a mechanical valve. Mechanical valves have the disad-
vantage of requiring anticoagulation, although, newer 
generations require a lower level of anticoagulation.30 
Whilst mechanical valves are more durable, this has to 
be balanced against the greater risk of bleeding.29 At 15 
years follow- up, Chiang et al also demonstrated no signif-
icant difference in survival and stroke between patients 
who underwent SAVR with mechanical vs bioprosthetic 
valve.29 Another group demonstrated in the 50–70 years 
old cohort that survival at 5 years was higher in patients 
who had undergone SAVR with mechanical valve versus 
bioprosthesis and also demonstrated similar freedom 
from major bleeding events.31
Bicuspid aortic valve and aneurysm of the aorta
A significant number of patients requiring SAVR have 
bicuspid aortic valve, which has an incidence of 1%–2% 
in the general population and may present with aortic 
valve stenosis, regurgitation and ascending aortic aneu-
rysm. The type of native aortic valve is not recorded in 
the database of our study. BAV may be present in up 
to 30% of patients undergoing SAVR.32 Bicuspid aortic 
valve anatomy, larger annular size, bulky and asymmetric 
leaflet calcification and dilated ascending aorta all pose 
technical challenges to TAVI which are not prohibitive 
risk factors for surgery. In fact, associated pathology of 
aneurysms of the aortic root and ascending aorta can be 
treated at the time of SAVR with little additional risk.33
European guidelines recommend discussing people 
with aortic valve disease in a multidisciplinary setting 
referred to as Heart Team, comprising of a surgeon, a 
non- interventional and an interventional cardiologist.34 
This will allow the best treatment option to be put forward 
to the person.
CONCLUSIONS
SAVR with and without CABG has low mortality risk and 
a low level of complications in the UK in people of all 
ages and risk factors. Our study provides real- world expe-
rience of surgical results to improve understanding of 
the risks of surgery and decision making in a multidisci-
plinary team setting with heart team. The results of this 
study can be used by people with aortic valve disease, 
referring general practitioners, physicians, surgeons and 
policy- makers. Future studies need to address long- term 
follow- up including factors like quality of life which are 
currently not collected by the specialist centres.
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